Zimmer Biomet Beats Quarterly Profit and Revenue Targets on High Hip and Knee Device Sales
Zimmer Biomet beat quarterly estimates today behind strong hip and knee device demand. The company expects lower 2026 profits due to a US sales model shift.
Insights:
Zimmer Biomet Holdings, Inc. reported fourth-quarter profit and revenue that surpassed Wall Street estimates on Tuesday, driven by strong demand for its hips and knees devices. The results reflect sustained joint-replacement procedural volumes across the US 
US, even as the company issued 2026 earnings guidance that fell below the average expectations of analysts.
US, even as the company issued 2026 earnings guidance that fell below the average expectations of analysts.For the fourth quarter, the medical device maker posted net sales of $2.24 billion and adjusted earnings per share of $2.42, beating the figures anticipated by the market. This performance was largely underpinned by the Zimmer Biomet hips segment and the Zimmer Biomet knees segment, both of which benefited from a continued recovery in elective surgeries.
